Evidence map›Paper›PMID 40160561›Full record

ReviewReviews in cardiovascular medicine2025

Modified Metabolic Syndrome Criteria Considering Cardio-Ankle Vascular Index (CAVI) and A Body Shape Index (ABSI): Implications for Kidney Risk.

Daiji Nagayama, Yasuhiro Watanabe, Kohji Shirai, Masahiro Ohira, Atsuhito Saiki

Abstract readReview
In one paragraph

Review in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daiji NagayamaDepartment of Internal Medicine, Nagayama Clinic, 323-0032 Oyama, Tochigi, Japan.ORCID https://orcid.org/0000-0001-6119-8012
Yasuhiro WatanabeCenter of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center, 285-0841 Sakura, Chiba, Japan.ORCID https://orcid.org/0000-0002-9614-162X
Kohji ShiraiDivision of Diabetes, Metabolism and Endocrinology, Toho University, Ohashi Medical Center, Meguro-Ku, 153-8515 Tokyo, Japan.ORCID https://orcid.org/0000-0003-1189-2668
Masahiro OhiraDepartment of Internal Medicine, Mihama Hospital, 261-0013 Chiba, Chiba, Japan.ORCID https://orcid.org/0000-0002-1935-6125
Atsuhito SaikiCenter of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center, 285-0841 Sakura, Chiba, Japan.ORCID https://orcid.org/0000-0003-4009-9386

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Waist circumference (WC), an abdominal obesity index in the current metabolic syndrome (MetS) criteria, may not adequately reflect visceral fat accumulation. This brief review aims to examine the clinical significance of utilizing a body shape index (ABSI), a novel abdominal obesity index, to modify the MetS criteria, considering the predictive ability for vascular dysfunction indicated by the cardio-ankle vascular index (CAVI), as well as kidney function decline. First, the relationship of CAVI with kidney function is presented. Next, whether modification of the MetS diagnostic criteria by replacing the current high waist circumference (WC-MetS) with high ABSI (ABSI-MetS) improves the predictive ability for vascular and kidney dysfunction is discussed. Although limited to Asian populations, several cross-sectional and longitudinal studies support the relationship of CAVI with kidney function. Increased CAVI is associated with kidney function decline, and the CAVI cutoff for kidney outcomes is considered to be 8-9. In urban residents who underwent health screening, an increase in ABSI, but not body mass index (BMI) or WC, was associated with increased CAVI, suggesting that ABSI reflects vasoinjurious body composition. In several cross-sectional studies, ABSI-MetS was superior to WC-MetS in identifying individuals with increased CAVI. Furthermore, the predictive ability of ABSI-MetS in assessing kidney function decline was enhanced only in individuals with MetS, as determined in a longitudinal analysis. Using WC as a major criterion for MetS diagnosis may not adequately identify individuals at risk of vascular dysfunction and kidney function decline. This review shows that this problem may be solved by replacing WC with ABSI. Future research should explore whether ABSI-MetS also predicts cardiovascular events, and whether therapeutic intervention that reduces ABSI improves clinical outcomes.

Indexed as

a body shape indexcardio-ankle vascular indexkidney function declinemetabolic syndromevascular functionwaist circumference

Identifiers

PMID40160561
PMCPMC11951487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.